Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib and Vinblastine for Pediatric Low-grade Glioma
NCT06666348Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire Sainte-Justine
- Start
- Jan 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in pediatric low-grade glioma (pLGG), sponsored by Centre Hospitalier Universitaire Sainte-Justine. Primary endpoints: Maximum Tolerated Dose at 3 years and Objective Response Rate at 5 years. Started Jan 2026; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
pediatric low-grade glioma (pLGG)
Beyond the preview
Go deeper on NCT06666348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666348.